Hypothesis

Young‑onset CRC arises from focal, transient epigenetic shocks in the distal colon triggered by diet‑microbiome interactions that overwhelm local mismatch repair, whereas late‑onset CRC stems from a diffuse, age‑dependent decline in mismatch repair proteins across the whole colon, producing a broad field of epigenetically altered crypts.

Mechanistic Basis

• In individuals <50 y, high‑fat, low‑fiber diets promote a mucosal microbiome enriched in bile‑acid‑tolerant anaerobes (e.g., Bilophila wadsworthia) that generate reactive oxygen species and inhibit DNA methyltransferase activity at specific CpG shores, producing sharp, focal hyper‑methylation of tumor suppressor promoters (e.g., SFRP2, MGMT) within 2‑5 crypt units.
• This focal shock creates a transient mismatch repair deficit limited to the affected crypt clusters, sufficient to initiate mutagenesis but not to sustain a widespread field.
• With advancing age, cumulative oxidative stress and inflammaging drive a gradual, colon‑wide reduction in MMR protein expression (PMS2, MLH1) via epigenetic silencing of their promoters and impaired proteostasis, resulting in a diffuse field cancerization where methylation frequencies exceed 50 % for markers such as SFRP2 up to 10 cm from any lesion.
• Consequently, the epigenetic landscape of normal‑appearing mucosa differs: young‑onset shows patchy, high‑amplitude methylation peaks; late‑onset exhibits low‑grade, uniform methylation across large distances.

Testable Predictions

1. Bisulfite sequencing of normal mucosa from patients <50 y will reveal methylation hotspots confined to <5 crypt clusters, predominantly in the distal colon, while patients ≥65 y will show homogeneous methylation extending >10 crypt units throughout the colon.
2. Microbiome profiling will correlate the abundance of bile‑acid‑resistant taxa with the intensity and focality of methylation hotspots in young‑onset cases.
3. Immunohistochemistry for PMS2 will display sporadic loss limited to hotspot crypts in young‑onset tissue, whereas age‑matched controls will exhibit a gradual, gradient loss of PMS2 from proximal to distal colon.
4. Experimental organoid cultures exposed to deoxycholic acid will acquire focal SFRP2 methylation and transient MMR suppression, reversible upon antioxidant treatment, mimicking the young‑onset pattern.

Experimental Approach

• Collect paired tumor‑adjacent normal biopsies from distal colon of 30 young‑onset (<50 y) and 30 late‑onset (≥65 y) CRC patients.
• Perform targeted bisulfite amplicon sequencing for SFRP2, MGMT, MLH1 promoters across serial crypt sections (0, 2, 5, 10 crypts from the lesion).
• Conduct 16S rRNA sequencing and metabolomics (bile acids, SCFA) on the same samples.
• Quantify PMS2/MLH1 protein by immunofluorescence and compute a spatial decay constant.
• Validate causality using human colonic organoids treated with deoxycholic acid ± N‑acetylcysteine, measuring methylation kinetics and MMR activity over time.

If the data show focal, microbiome‑linked methylation hotspots and transient MMR loss in young‑onset specimens alongside a diffuse, age‑graded MMR decline in late‑onset cases, the hypothesis is supported; converse patterns would falsify it.